Afatinib-loaded Inhalable PLGA Nanoparticles for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC) – Development and In-vitro Efficacy

Afatinib (AFA) is a potent aniline-quinazoline derivative, approved by the Food and Drug Administration (FDA) in 2013, as a first-line treatment for metastatic Non-Small Cell Lung Cancer (NSCLC). However, its clinical application is highly limited by its poor solubility, and consequently low bioavai...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drug Deliv Transl Res
Autors principals: Elbatanony, Rasha S., Parvathaneni, Vineela, Kulkarni, Nishant S, Shukla, Snehal K, Chauhan, Gautam, Kunda, Nitesh K, Gupta, Vivek
Format: Artigo
Idioma:Inglês
Publicat: 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7738377/
https://ncbi.nlm.nih.gov/pubmed/32557351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13346-020-00802-8
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars